Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?
It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company…
BioMarin Pays $275M Upfront for Alesta to Challenge AstraZeneca in Rare Bone Disease — BigGo Finance
BioMarin Pharmaceutical Inc. (BMRN) has agreed to acquire Alesta Therapeutics for $275 million in upfront cash, securing an…
Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?
In the life sciences sector, capital allocation often tells a clearer story than pure drug discovery. While pharmaceutical…
Do Options Traders Know Something About AstraZeneca Stock We Don’t?
Investors in AstraZeneca PLC AZN need to pay close attention to the stock based on moves in the…
AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk
AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock’s biggest one-day drop since…
Hedge Funds are Bullish on AstraZeneca PLC (AZN)
AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts…
Hedge Funds are Bullish on AstraZeneca PLC (AZN)
AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts…
Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?
It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company…
AstraZeneca held talks with Bristol Myers Squibb on $400 billion megadeal, source says
By Sabrina Valle and Michael Erman Aug 2 (Reuters) – AstraZeneca Plc and Bristol Myers Squibb held preliminary…
AstraZeneca slides 7% after report of merger talks with Bristol Myers Squibb
Investing.com — AstraZeneca PLC (LON:AZN) shares fell nearly 7% in London trading on Monday after a report said…
AstraZeneca-Bristol Myers merger talks explained
Pharma investors reeled this week from reports that AstraZeneca held merger talks with U.S. rival Bristol Myers Squibb,…
AstraZeneca stock falls as investors balk at reported Bristol Myers tie-up
AstraZeneca shares dropped as much as 7% on Monday after reports that the company had discussed a potential…